ArticleThe American journal of pathology2003
Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Article in The American journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 1 synthesis or guideline pooled it, 312 citations in OpenAlex.
- Pooled it
- Efficacious Anti-Cancer Drugs Targeting NicotinamidePharmaceuticals (Basel, Switzerland) · 2026Article
- Salvage Surgery for Localized Recurrent Ovarian Clear Cell Carcinoma: A Retrospective Case Series.Gynecologic and obstetric investigation · 2026Article
- Diagnostic and prognostic biomarkers associated with histotype in advanced epithelial ovarian cancer.Scientific reports · 2025Article
- Cystathionine gamma-lyase-mediated hypoxia inducible factor 1-alpha expression drives clear cell ovarian cancer progression.The Journal of pathology · 2025Article
- Distinct endometriosis involvement confers divergent oncologic outcomes in ovarian clear cell carcinoma.Archives of gynecology and obstetrics · 2025Article
- Borderline ovarian clear cell tumor arising from endometriosis during long-term dienogest therapy: a case report.Frontiers in oncology · 2025Article
- HNF-1β alleviates podocyte injury in lupus nephritis by maintaining endoplasmic reticulum homeostasis.Lupus science & medicine · 2024Article
- Deciphering tumour microenvironment and elucidating the origin of cancer cells in ovarian clear cell carcinoma.bioRxiv : the preprint server for biology · 2024Article
- Status and development of research on clear cell carcinoma of the ovary-a visualization-based bibliometric analysis.Translational cancer research · 2024Article
- Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese.Human genomics · 2024Article
- Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis.Fukushima journal of medical science · 2024Article
- From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.Journal of ovarian research · 2024Review
- Cell State of Origin Impacts Development of Distinct Endometriosis-Related Ovarian Carcinoma Histotypes.Cancer research · 2024Article
- Heterogeneity and treatment landscape of ovarian carcinoma.Nature reviews. Clinical oncology · 2023Review
- Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing.Current oncology (Toronto, Ont.) · 2023Article
- Exploring the cellular and molecular differences between ovarian clear cell carcinoma and high-grade serous carcinoma using single-cell RNA sequencing and GEO gene expression signatures.Cell & bioscience · 2023Article
- Review
- Diagnostic Accuracy of Alpha-Methylacyl-CoA Racemase Immunohistochemical Expression for the Diagnosis of Ovarian and Endometrial Clear Cell Carcinomas.Iranian journal of pathology · 2023Article
- Hierarchical deconvolution for extensive cell type resolution in the human brain using DNA methylation.Frontiers in neuroscience · 2023Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of all of the epithelial ovarian cancers, clear cell carcinoma (CCC) of the ovary has the worst prognosis. We applied the oligonucleotide array technique to identify genes generally involved in CCC. Of the approximately 12,600 genes that were analyzed, 28 were expressed significantly differently between four CCC and seven non-CCC cell lines. Among 16 up-regulated genes in CCC, we further investigated a transcription factor, hepatocyte nuclear factor-1 beta (HNF-1 beta). We validated up-regulation of HNF-1 beta in CCC in terms of both mRNA and protein level using real-time quantitative reverse transcriptase-polymerase chain reaction and immunoblotting. Immunohistochemical analysis of 83 surgically resected ovarian cancers showed that almost all CCC specimens (21 of 22 cases) had nuclear staining for HNF-1 beta, whereas most non-CCC specimens (60 of 61 cases) showed no immunostaining or only focal and faint staining in the nucleus. Furthermore, we investigated the significance of HNF-1 beta expression in CCC using RNA interference. The reduction of HNF-1 beta expression by RNA interference induced apoptotic cell death in ovarian CCC cells, which was confirmed by terminal dUTP nick-end labeling and fluorescence-activated cell-sorting analyses. Our results suggest that HNF-1 beta is not only an excellent CCC-specific molecular marker but also a molecular target for therapy of ovarian CCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.